Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | KMO | O15229 | 3/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.35 |
| ▸ | PLK1 | P53350 | 1/20 | 0.34 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.33 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | ERN1 | O75460 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17687914 | 0.80 | CYP11B2 (0.43) | CYP19A1IDO1ERN1 | |
| SCHEMBL19762806 | 0.80 | IDO1 (0.50) | JAK2KMOGSK3BPLK1HSD17B1 | |
| SCHEMBL28778071 | 0.76 | MAP4K4 (0.49) | KMONFE2L2PLK1CYP19A1IDO1 | |
| SCHEMBL7609085 | 0.75 | ERN1 (0.38) | KMOCYP3A4ERN1 | |
| SCHEMBL27751607 | 0.71 | MAP4K4 (0.46) | JAK2KMOGSK3BNFE2L2CYP3A4 | |
| SCHEMBL27772385 | 0.71 | CYP2A6 (0.42) | JAK2NFE2L2ERN1 | |
| SCHEMBL25392607 | 0.71 | KMO (0.38) | KMOIDO1 | |
| SCHEMBL31282190 | 0.71 | KMO (0.38) | KMOIDO1 | |
| SCHEMBL2084619 | 0.71 | EGFR (0.45) | ERN1 | |
| SCHEMBL29935212 | 0.71 | EGFR (0.45) | ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3207042-B1 | ANTIBACTERIAL BASIC BIAROMATIC DERIVATIVES WITH AMINOALKOXY SUBSTITUTION | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-10-03 | — | — | EP | disclosed |
| US-9850256-B2 | Antibacterial basic biaromatic derivatives with aminoalkoxy substitution | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-12-26 | — | — | US | disclosed |
| US-20170305927-A1 | ANTIBACTERIAL BASIC BIAROMATIC DERIVATIVES WITH AMINOALKOXY SUBSTITUTION | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305927-A1 | ANTIBACTERIAL BASIC BIAROMATIC DERIVATIVES WITH AMINOALKOXY SUBSTITUTION | RPSA, RPL4, RPS4Y1 | JAK2 2268/4885KMO 1572/4885GSK3B 4291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.